236 related articles for article (PubMed ID: 31507604)
1. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
2. Functional and structural insight into properdin control of complement alternative pathway amplification.
Pedersen DV; Roumenina L; Jensen RK; Gadeberg TA; Marinozzi C; Picard C; Rybkine T; Thiel S; Sørensen UB; Stover C; Fremeaux-Bacchi V; Andersen GR
EMBO J; 2017 Apr; 36(8):1084-1099. PubMed ID: 28264884
[TBL] [Abstract][Full Text] [Related]
3. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
Front Immunol; 2019; 10():2097. PubMed ID: 31552043
[TBL] [Abstract][Full Text] [Related]
4. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterisation of the thrombospondin type I repeats of human properdin.
Perdikoulis MV; Kishore U; Reid KB
Biochim Biophys Acta; 2001 Aug; 1548(2):265-77. PubMed ID: 11513971
[TBL] [Abstract][Full Text] [Related]
6. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
8. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
9. Crystallization and X-ray analysis of monodisperse human properdin.
Pedersen DV; Revel M; Gadeberg TAF; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2019 Feb; 75(Pt 2):0. PubMed ID: 30713161
[TBL] [Abstract][Full Text] [Related]
10. Structure determination of an unstable macromolecular complex enabled by nanobody-peptide bridging.
Lorentzen J; Pedersen DV; Gadeberg TAF; Andersen GR
Protein Sci; 2022 Oct; 31(10):e4432. PubMed ID: 36173177
[TBL] [Abstract][Full Text] [Related]
11. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
12. Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function.
Higgins JM; Wiedemann H; Timpl R; Reid KB
J Immunol; 1995 Dec; 155(12):5777-85. PubMed ID: 7499866
[TBL] [Abstract][Full Text] [Related]
13. A recombinant two-module form of human properdin is an inhibitor of the complement alternative pathway.
Kouser L; Abdul-Aziz M; Tsolaki AG; Singhal D; Schwaeble WJ; Urban BC; Khan HA; Sim RB; Kishore U
Mol Immunol; 2016 May; 73():76-87. PubMed ID: 27060503
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
15. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
16. Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond.
Pedersen DV; Lorentzen J; Andersen GR
Immunol Rev; 2023 Jan; 313(1):46-59. PubMed ID: 36097870
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
[TBL] [Abstract][Full Text] [Related]
18. Neutron and X-ray scattering studies on the human complement protein properdin provide an analysis of the thrombospondin repeat.
Smith KF; Nolan KF; Reid KB; Perkins SJ
Biochemistry; 1991 Aug; 30(32):8000-8. PubMed ID: 1868073
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
